Quaschning T, Mainka T, Nauck M, Rump L C, Wanner C, Krämer-Guth A
Department of Medicine, University of Würzburg, Germany.
Kidney Int Suppl. 1999 Jul;71:S235-7. doi: 10.1046/j.1523-1755.1999.07162.x.
Patients after renal transplantation exhibit high cardiovascular morbidity and mortality because of the accumulation of cardiovascular risk factors such as hypertension or dyslipidemia. To elucidate the influence of immunosuppressive therapy on hyperlipidemia, we studied serum lipids and lipoproteins in renal transplant patients who received prednisone and either azathioprine or cyclosporine or triple immunosuppressive therapy.
Serum lipids and lipoprotein levels were measured in 216 renal transplant patients (81 female and 135 male) with stable graft function of 4.8 +/- 2.3 years (range six months to eight years) after transplantation. Patients were divided into three groups according to one of the following immunosuppressive regimens: (a) prednisone and azathioprine, (b) prednisone and cyclosporine, or (c) prednisone, azathioprine, and cyclosporine. Healthy, age- and sex-matched subjects served as controls. In addition to measurement of total serum lipids, lipoproteins were isolated by preparative ultracentrifugation, and lipids were determined in very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) density classes.
Total serum triglycerides, VLDL, and LDL triglycerides, as well as VLDL cholesterol were elevated in all renal transplant patients, but elevation was pronounced in female patients. In contrast to total serum cholesterol, which was significantly increased in only female patients, elevation of LDL-triglyceride/apo B ratio was more marked in male patients. Patients in group A exhibited only mild hypertriglyceridemia, whereas triglyceride enrichment in VLDL and LDL was more distinct in group B and was most pronounced in patients of group C. Furthermore, hypertriglyceridemia increased with the dose of administered prednisone.
Immunosuppressive therapy in renal transplant patients leads to accumulation of triglyceride-enriched VLDL and LDL. Triglyceride enrichment in LDL indicates the accumulation of small, dense LDLs, which are known to bear enhanced atherosclerotic risk. This study provides data that underline the use of individually adjusted immunosuppressive therapy and steroid-sparing protocols in renal transplant patients to improve their atherogenic lipoprotein profile.
肾移植后的患者由于高血压或血脂异常等心血管危险因素的积累,心血管发病率和死亡率较高。为了阐明免疫抑制治疗对高脂血症的影响,我们研究了接受泼尼松和硫唑嘌呤或环孢素或三联免疫抑制治疗的肾移植患者的血脂和脂蛋白情况。
对216例肾移植患者(81例女性,135例男性)进行了血脂和脂蛋白水平测定,这些患者移植后移植肾功能稳定4.8±2.3年(范围为6个月至8年)。根据以下免疫抑制方案之一将患者分为三组:(a)泼尼松和硫唑嘌呤,(b)泼尼松和环孢素,或(c)泼尼松、硫唑嘌呤和环孢素。健康的、年龄和性别匹配的受试者作为对照。除了测定总血脂外,通过制备超速离心法分离脂蛋白,并测定极低密度脂蛋白(VLDL)、低密度脂蛋白(LDL)和高密度脂蛋白(HDL)密度级别的脂质。
所有肾移植患者的总血清甘油三酯、VLDL和LDL甘油三酯以及VLDL胆固醇均升高,但女性患者升高更为明显。与仅在女性患者中显著升高的总血清胆固醇不同,LDL-甘油三酯/载脂蛋白B比值在男性患者中升高更为明显。A组患者仅表现为轻度高甘油三酯血症,而B组患者VLDL和LDL中的甘油三酯富集更为明显,C组患者最为显著。此外,高甘油三酯血症随泼尼松给药剂量的增加而加重。
肾移植患者的免疫抑制治疗导致富含甘油三酯的VLDL和LDL积聚。LDL中的甘油三酯富集表明小而密LDL的积聚,已知其具有增强的动脉粥样硬化风险。本研究提供的数据强调了在肾移植患者中使用个体化调整的免疫抑制治疗和类固醇节约方案以改善其致动脉粥样硬化脂蛋白谱的必要性。